価格表

在庫・価格 : 2025年04月26日 10時05分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Recombinant Human R-Spondin 3 (25 UG)
データシート
3500-RS-025 RSDアールアンドディー システムズ
R&D Systems, Inc.
25 μg ¥86,000
(未発注)
追加

在庫・価格 : 2025年04月26日 10時05分 現在

Recombinant Human R-Spondin 3 (25 UG)

  • 商品コード:3500-RS-025
  • メーカー:RSD
  • 包装:25μg
  • 価格: ¥86,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Hao HX et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012 May;485(7397):195-200
Hao HX et al
2012/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
2 Wilson TR et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 Jul;487(7408):505-9
Wilson TR et al
2012/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
3 Xie Y et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin. EMBO Rep. 2013 Dec;14(12):1120-6
Xie Y et al
2013/01/01
Application: cell culture, Sample Type: whole cells PubMed
4 Wu C et al. RSPO2-LGR5 signaling has tumour-suppressive activity in colorectal cancer. Nat Commun 2014;5:3149
Wu C et al
2014/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
5 Carmon KS et al. RSPO-LGR4 functions via IQGAP1 to potentiate Wnt signaling. Proc. Natl. Acad. Sci. U.S.A. 2014 Apr;111(13):E1221-9
Carmon KS et al
2014/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
6 Chartier C et al. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. Cancer Res. 2016 Feb;76(3):713-23
Chartier C et al
2016/01/01
Application: Bioassay, Sample Type: In Vivo PubMed
7 Zeve D et al. Exercise-Induced Skeletal Muscle Adaptations Alter the Activity of Adipose Progenitor Cells. PLoS ONE 2016;11(3):e0152129
Zeve D et al
2016/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
  • No.: 1
  • 文献情報:
    Hao HX et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012 May;485(7397):195-200
    Hao HX et al
    2012/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Wilson TR et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 Jul;487(7408):505-9
    Wilson TR et al
    2012/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Xie Y et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin. EMBO Rep. 2013 Dec;14(12):1120-6
    Xie Y et al
    2013/01/01
  • 備考:
    Application: cell culture, Sample Type: whole cells
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Wu C et al. RSPO2-LGR5 signaling has tumour-suppressive activity in colorectal cancer. Nat Commun 2014;5:3149
    Wu C et al
    2014/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Carmon KS et al. RSPO-LGR4 functions via IQGAP1 to potentiate Wnt signaling. Proc. Natl. Acad. Sci. U.S.A. 2014 Apr;111(13):E1221-9
    Carmon KS et al
    2014/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Chartier C et al. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. Cancer Res. 2016 Feb;76(3):713-23
    Chartier C et al
    2016/01/01
  • 備考:
    Application: Bioassay, Sample Type: In Vivo
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Zeve D et al. Exercise-Induced Skeletal Muscle Adaptations Alter the Activity of Adipose Progenitor Cells. PLoS ONE 2016;11(3):e0152129
    Zeve D et al
    2016/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed